Tilray (NASDAQ:TLRY) PT Lowered to $1.75 at Roth Mkm

Tilray (NASDAQ:TLRY) had its price target decreased by Roth Mkm from $2.00 to $1.75 in a research report report published on Friday, Benzinga reports. Roth Mkm currently has a neutral rating on the stock.

Tilray Stock Performance

Shares of TLRY opened at $1.63 on Friday. The company has a quick ratio of 1.42, a current ratio of 2.27 and a debt-to-equity ratio of 0.10. Tilray has a 52-week low of $1.45 and a 52-week high of $2.97. The company has a 50-day simple moving average of $1.75 and a 200-day simple moving average of $1.86. The company has a market capitalization of $1.37 billion, a PE ratio of -6.04 and a beta of 2.13.

Tilray (NASDAQ:TLRY) last issued its earnings results on Thursday, October 10th. The company reported ($0.04) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.04). Tilray had a negative net margin of 26.79% and a negative return on equity of 2.01%. The company had revenue of $200.00 million during the quarter, compared to analysts’ expectations of $218.70 million. During the same period last year, the company posted ($0.10) earnings per share. The firm’s quarterly revenue was up 13.0% compared to the same quarter last year. Equities research analysts predict that Tilray will post -0.16 earnings per share for the current fiscal year.

Institutional Trading of Tilray

Institutional investors have recently bought and sold shares of the company. Wellington Wealth Strategies LLC. acquired a new position in shares of Tilray during the 4th quarter worth $29,000. HBK Sorce Advisory LLC purchased a new stake in shares of Tilray in the first quarter valued at about $37,000. Prospect Financial Services LLC acquired a new stake in shares of Tilray in the second quarter valued at approximately $26,000. Signature Estate & Investment Advisors LLC purchased a new position in shares of Tilray during the 2nd quarter worth approximately $29,000. Finally, HighPoint Advisor Group LLC acquired a new position in shares of Tilray during the 4th quarter worth approximately $43,000. 9.35% of the stock is currently owned by hedge funds and other institutional investors.

About Tilray

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.